WO2004073596A3 - Composition vaccinale comprenant un antigene proteique du vih incorpore dans des vesicules lipidiques multilamellaires. - Google Patents

Composition vaccinale comprenant un antigene proteique du vih incorpore dans des vesicules lipidiques multilamellaires. Download PDF

Info

Publication number
WO2004073596A3
WO2004073596A3 PCT/FR2004/050052 FR2004050052W WO2004073596A3 WO 2004073596 A3 WO2004073596 A3 WO 2004073596A3 FR 2004050052 W FR2004050052 W FR 2004050052W WO 2004073596 A3 WO2004073596 A3 WO 2004073596A3
Authority
WO
WIPO (PCT)
Prior art keywords
multilamellar
hiv
vaccine composition
antigen incorporated
incorporated
Prior art date
Application number
PCT/FR2004/050052
Other languages
English (en)
Other versions
WO2004073596A2 (fr
Inventor
Sophie Gaubert
Marie-Josephe Dallot
Rene Laversanne
Original Assignee
Ethypharm Sa
Sophie Gaubert
Marie-Josephe Dallot
Rene Laversanne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ethypharm Sa, Sophie Gaubert, Marie-Josephe Dallot, Rene Laversanne filed Critical Ethypharm Sa
Publication of WO2004073596A2 publication Critical patent/WO2004073596A2/fr
Publication of WO2004073596A3 publication Critical patent/WO2004073596A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition pharmaceutique contenant une dispersion ou une suspension dans un véhicule pharmaceutiquement acceptable de vésicules multilamellaires à structure interne cristal-liquide, formées d'un empilement de bicouches concentriques à base d'agents amphiphiles alternant avec des couches d'eau, de solution aqueuse, de liquide polaire ou de solution d'un liquide polaire, et au sein desquelles se trouve incorporé au moins un antigène protéique du virus VIH. L'antigène est en particulier la protéine P 24. La composition permet d'amplifier et d'orienter la réponse immunitaire induite contre cet antigène aussi bien par injection qu'après administration par voie muqueuse.
PCT/FR2004/050052 2003-02-12 2004-02-06 Composition vaccinale comprenant un antigene proteique du vih incorpore dans des vesicules lipidiques multilamellaires. WO2004073596A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0301658A FR2850872A1 (fr) 2003-02-12 2003-02-12 Composition vaccinale destinee a induire une reponse immunitaire contre le virus responsable du sida
FR03/01658 2003-02-12

Publications (2)

Publication Number Publication Date
WO2004073596A2 WO2004073596A2 (fr) 2004-09-02
WO2004073596A3 true WO2004073596A3 (fr) 2004-10-28

Family

ID=32731973

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2004/050052 WO2004073596A2 (fr) 2003-02-12 2004-02-06 Composition vaccinale comprenant un antigene proteique du vih incorpore dans des vesicules lipidiques multilamellaires.

Country Status (2)

Country Link
FR (1) FR2850872A1 (fr)
WO (1) WO2004073596A2 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995022961A1 (fr) * 1994-02-23 1995-08-31 Institut Pasteur Liposomes, et leur utilisation notamment pour l'obtention de compositions immunomodulatrices
US5679355A (en) * 1992-04-07 1997-10-21 Proteus Molecular Design Limited Vaccines containing non-ionic surfactant vesicles
WO1999000142A1 (fr) * 1997-06-26 1999-01-07 Bio-Sphere Technology, Inc. Methode pour provoquer une reponse immunitaire systemique a un antigene de l'hepatite ou du vih
WO1999004412A2 (fr) * 1997-07-18 1999-01-28 Von Ardenne Anlagentechnik Gmbh Ensemble cathode cible
WO1999016468A1 (fr) * 1997-09-29 1999-04-08 Capsulis Vecteurs d'antigenes sous forme de vesicules multilamellaires
WO2001019335A2 (fr) * 1999-09-14 2001-03-22 Capsulis Compositions destinees a une administration par voie muqueuse
US20020142030A1 (en) * 1996-03-22 2002-10-03 Oral Vaccine Technologies, Inc. Method for inducing a systemic immune response to an HIV antigen

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679355A (en) * 1992-04-07 1997-10-21 Proteus Molecular Design Limited Vaccines containing non-ionic surfactant vesicles
WO1995022961A1 (fr) * 1994-02-23 1995-08-31 Institut Pasteur Liposomes, et leur utilisation notamment pour l'obtention de compositions immunomodulatrices
US20020142030A1 (en) * 1996-03-22 2002-10-03 Oral Vaccine Technologies, Inc. Method for inducing a systemic immune response to an HIV antigen
WO1999000142A1 (fr) * 1997-06-26 1999-01-07 Bio-Sphere Technology, Inc. Methode pour provoquer une reponse immunitaire systemique a un antigene de l'hepatite ou du vih
WO1999004412A2 (fr) * 1997-07-18 1999-01-28 Von Ardenne Anlagentechnik Gmbh Ensemble cathode cible
WO1999016468A1 (fr) * 1997-09-29 1999-04-08 Capsulis Vecteurs d'antigenes sous forme de vesicules multilamellaires
WO2001019335A2 (fr) * 1999-09-14 2001-03-22 Capsulis Compositions destinees a une administration par voie muqueuse

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GENTY M ET AL: "Complex dispersions of multilamellar vesicles: a promising new carrier for controlled release and protection of encapsulated molecules", JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 90, no. 1, 5 June 2003 (2003-06-05), pages 119 - 133, XP004427411, ISSN: 0168-3659 *
VANCOTT T C ET AL: "HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp160.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD.: 1950) UNITED STATES 15 FEB 1998, vol. 160, no. 4, 15 February 1998 (1998-02-15), pages 2000 - 2012, XP002254827, ISSN: 0022-1767 *
WASSEF N M ET AL: "LIPOSOMES AS CARRIERS FOR VACCINES", IMMUNOMETHODS, vol. 4, 1 June 1994 (1994-06-01), pages 217 - 222, XP000601673, ISSN: 1058-6687 *

Also Published As

Publication number Publication date
WO2004073596A2 (fr) 2004-09-02
FR2850872A1 (fr) 2004-08-13

Similar Documents

Publication Publication Date Title
Chatzikleanthous et al. Lipid-based nanoparticles for delivery of vaccine adjuvants and antigens: toward multicomponent vaccines
US10525121B2 (en) Nanoemulsion influenza vaccine
ES2279625T3 (es) Compuesto y procedimiento para la prevencion y/o el tratamiento de la alergia.
ES2257072T3 (es) Composicion de vacuna antigripal.
WO2002028427A3 (fr) Composition pharmaceutique pour l'immunisation contre le sida
DK2353608T3 (da) Polypeptid-vacciner til bred beskyttelse mod hypervirulente meningokok-linjer
WO1996040057A3 (fr) Compositions a emulsions de fluorocarbone inverses pour l'administration de medicaments
EP2278012A3 (fr) Flavivirus chimériques avirulents et immunogènes
PE20040562A1 (es) Vacunas que comprenden mezclas de cepas meningococicas multivalentes
JP2010500399A5 (fr)
CA3023672A1 (fr) Liposomes pegyles et procedes d'utilisation
WO2003028757A1 (fr) Nouvelle methode pour induire des lymphocytes t specifiques d'antigenes
Wang et al. Nanotechnology‐facilitated vaccine development during the coronavirus disease 2019 (COVID‐19) pandemic
EP2753354A1 (fr) Vaccin sous-unitaire contre le virus respiratoire syncytial (rsv) en nano-émulsion
US7596836B2 (en) Nose and throat anti-influenza solution and method of use
WO2004073596A3 (fr) Composition vaccinale comprenant un antigene proteique du vih incorpore dans des vesicules lipidiques multilamellaires.
Tiwari et al. Immunoglobulin immobilized liposomal constructs for transmucosal vaccination through nasal route
Van Slooten et al. Immunoadjuvant activity of interferon-γ-liposomes co-administered with influenza vaccines
ATE251894T1 (de) Pharmazeutische zusammensetzungen zur oralen verabreichung
CA2420640A1 (fr) Preparations combinees de derives d'acide 3-n-formyl- hydroxyamino-propylphosphonique ou de derives d'acide 3-n- acethyl-hydroxyamino-propylphosphonique avec ingredients speciaux pharmaceutiquement actifs
Masood et al. Immunomodulator tuftsin augments anti-fungal activity of amphotericin B against experimental murine candidiasis
WO2001019335A3 (fr) Compositions destinees a une administration par voie muqueuse
JP2015533821A5 (fr)
EA200300535A1 (ru) Способ получения антигенных структур, усиливающих специфическую перекрестную реактивность
ES2369949A1 (es) Microesferas poliméricas como adyuvantes en la producción de vacunas frente a parásitos escuticociliados de peces.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase